PROGRAM

"Your meetings are the best I've been to..."

17th WCIRDC Attendee Comments

 

Program Description

The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 18th year, is a unique and exciting multidisciplinary CME program. The Congress is the premier global meeting dedicated to diabetes, obesity, lipids, cardiovascular-kidney and liver disease linking basic research to clinical practice in pursuit of our theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.
 

This year, due to the pandemic, the Congress, originally planned for Los Angeles, goes virtual: Live-Interactive-Online over 4 days and will be available on-demand for 90 days. For the first time, the registration will be free, including 30 CME & ABIM-MOC credits.
 

For nearly two decades, WCIRDC has brought researchers, physicians, clinicians, and other healthcare professionals together for a distinctive international program that bridges the latest developments from bench-to-bedside. “I heard it first at the Congress” is a frequent remark from the audience. WCIRDC offers attendees a unique experience to interact with the distinguished global faculty for a collaborative experience that explores the newest understanding of metabolic diseases and the development of future therapeutic modalities. 


Since Dr. Gerald Reaven’s pioneering work crystallized the relationship between insulin resistance (IR), diabetes, obesity, and CVD, the Congress’ focus has expanded to cover the kidney, liver, brain, bone, cancer, and more.  The congress addresses dyslipidemia, atherosclerosis, hypertension,  hypercoagulation, inflammation, and energy metabolism. It provides the newest clinical updates on pharmaceutical interventions such as incretins, SGLT2i’s, PCSK9i’s, and EPA omega 3 to name a few, assessing their impact on practice. The goal is to understand the state-of-the-art pathophysiology, new medical interventions, and to develop appropriate comprehensive clinical management strategies.

 

To make basic and clinical research topics relevant to clinical medicine, following each session there will be live Q&A and a discussion on clinical implications to practice. To promote more interaction with faculty and provide further insights, each day will end with one hour of live panel, with a summary of the day’s sessions, commentary, and Q&A.

 

The Congress attracts state-of-the-art abstracts by young, up-and-coming researchers as well as recognized leaders from around the globe. The abstracts will be available for 90 days on the conference platform and published in Metabolism, a peer-reviewed journal, with over 40,000 unique monthly viewers worldwide, which is in the top 10% of endocrinology, diabetes, and metabolism journals.

Proceedings from the congress are featured in global medical news venues such as Healio, Medscape, Endocrinology & Cardiology Today, Clinical Endocrinology News and more, while articles are being published in peer-reviewed journals like Journal of Diabetes, Endocrine Practice, Metabolism, Diabetes & Vascular Disease Research, and others.

 

We welcome you to join us in this new phase of the congress. We are looking forward to the same success, with you, in our new platform, just as we had in the past 17 years.



 

Program Objectives

The program is designed to evaluate the clinical and basic science aspects of diabetes, obesity, HTN, dyslipidemia, CVD, HF, CKD, and related cardiometabolic conditions; focusing on basic science such as insulin resistance, hyperinsulinemia, fat, inflammation, and clinical practice; understanding cardiometabolic conditions. The goal is to understand the pathophysiology of each condition and develop appropriate comprehensive clinical management plans.

 

Upon completion of this meeting, participants should be able to:

  • Discuss COVID-19 and diabetes and Obesity.

  • Discuss Heart disease in women

  • Describe the relationship between diabetes, obesity, and heart failure

  • Discuss The etiology of Insulin resistance

  • Discuss T1D obesity and CVD

  • Discuss the effect of lipotoxicity and the pathophysiology of CVD

  • Discuss the role of obesity in the development of cardiometabolic conditions

  • Explain the roles of diabetes in the development of micro & macrovascular conditions: kidney disease, retinopathy, neuropathy, CVD, and strokes

  • Provide comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia, and hyperglycemia while focusing on preventing ASCVD

  • Discuss the role of GLP1ra in the management of diabetes, obesity, and prevention of ASCVD.

  • Evaluate SGLT2 inhibitors role in reducing cardiovascular morbidity & mortality in patients with and without T2D and at risk for or established CVD

  • Address SGLT2i role in managing patients with CKD and HFrEF

  • Explain the role of PCSK9 inhibitors in preventing CV morbidity in people with established ASCVD

  • Discuss fatty liver disease and its relationship to diabetes and CVD

  • Evaluate the impact on the clinical practice of recent CVD, CHF & CKD outcome trials

  • Evaluate the impact on the clinical practice of lipid CV outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-Outcomes

  • Analyze the Cardiorenal Syndrome

  • Examine the impact of Coagulation in diabetes in prevention of CVD and CVA

  • Technology in monitoring and reducing DM & ASCVD

 

 

Target Audience

This educational initiative is designed for cardiologists, endocrinologists, internists, PCPs, diabetologists, OBGYNs, pediatricians, gastroenterologists, oncologists, dietitians, nurse practitioners, physician assistances, pharmacists, and any other health care professionals who are interested in improving patients outcome.

Program Objectives

The program is designed to evaluate the clinical and basic science aspects of diabetes, obesity, HTN, dyslipidemia, CVD, HF, CKD, and related cardiometabolic conditions; focusing on basic science such as insulin resistance, hyperinsulinemia, fat, inflammation, and clinical practice; understanding cardiometabolic conditions. The goal is to understand the pathophysiology of each condition and develop appropriate comprehensive clinical management plans.

 

Upon completion of this meeting, participants should be able to:

  • - Discuss COVID-19 and diabetes and Obesity.

  •  

  • - Discuss Heart disease in women

  •  

  • - Describe the relationship between diabetes, obesity, and heart failure

  •  

  • - Discuss The etiology of Insulin resistance

  •  

  • - Discuss T1D obesity and CVD

  •  

  • - Discuss the effect of lipotoxicity and the pathophysiology of CVD

  •  

  • - Discuss the role of obesity in the development of cardiometabolic conditions

  •  

  • - Explain the roles of diabetes in the development of micro & macrovascular conditions: kidney disease, retinopathy, neuropathy, CVD, and strokes

  •  

  • - Provide comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia, and hyperglycemia while focusing on preventing ASCVD

  •  

  • - Discuss the role of GLP1ra in the management of diabetes, obesity, and prevention of ASCVD.

  •  

  • - Evaluate SGLT2 inhibitors role in reducing cardiovascular morbidity & mortality in patients with and without T2D and at risk for or established CVD

  •  

  • - Address SGLT2i role in managing patients with CKD and HFrEF

  •  

  • -Explain the role of PCSK9 inhibitors in preventing CV morbidity in people with established ASCVD

  •  

  • -Discuss fatty liver disease and its relationship to diabetes and CVD

  •  

  • - Evaluate the impact on the clinical practice of recent CVD, CHF & CKD outcome trials

  •  

  • - Evaluate the impact on the clinical practice of lipid CV outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-Outcomes

  •  

  • - Analyze the Cardiorenal Syndrome

  •  

  • - Examine the impact of Coagulation in diabetes in prevention of CVD and CVA

  • Technology in monitoring and reducing DM & ASCVD

  •  

 

Target Audience

This educational initiative is designed for cardiologists, endocrinologists, internists, PCPs, diabetologists, OBGYNs, pediatricians, gastroenterologists, oncologists, dietitians, nurse practitioners, physician assistances, pharmacists, and any other health care professionals who are interested in improving patients outcome.

Program Chair

Yehuda Handelsman, MD is an Endocrinologist with extensive experience in the clinical aspect of Diabetes and CVD and is well-versed in managing Hyperglycemia, HTN, Lipid disorders, and coagulation.

Dr. Handelsman is also an experienced clinical researcher and educator.

Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE

Chair & Program Director

18th WCIRDC

Medical Director & Principal Investigator

Metabolic Institute of America 

Chair & Founder

International Committee for Insulin Resistance

Tarzana, California

18372 Clark Street

Suite 212

Tarzana, CA 91356

info@tmioa.com

Phone: 818-342-1889
Fax: 818-342-1538

  • Facebook
  • Twitter

JOINTLY PROVIDED BY:

ADMINISTERED BY: